The human epidermal growth factor receptor 3 (HER3) is an interesting target for antitumor therapy. For optimal HER3 signaling inhibition, a biparatopic Nanobody construct (MSB0010853) was developed that binds 2 different HER3 epitopes. In addition, MSB0010853 contains a third HER3 epitope that binds albumin to extend its circulation time. MSB0010853 is cross-reactive with HER3 and albumin of mouse origin. We aimed to gain insight into MSB0010853 biodistribution and tumor uptake by radiolabeling the Nanobody construct with Zr-89. Methods: MSB0010853 was radiolabeled with Zr-89. Dose-and time-dependent tumor uptake was studied in nude BALB/c mice bearing a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft. Dose-depen...
Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kina...
Cancer Tissue-Originated Spheroid (CTOS) is a recently developed tissue culture method, in which the...
Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer)...
The human epidermal growth factor receptor 3 (HER3) is an interesting target for antitumor therapy. ...
The humanized monoclonal antibody with high affinity for the human epidermal growth factor receptor ...
PURPOSE: Human epidermal growth factor receptor type 3 (HER3) is a transmembrane receptor tyrosine k...
HER3 (human epidermal growth factor receptor type 3) is a challenging target for diagnostic radionuc...
The human epidermal growth factor receptor 3 (HER3) is involved in the development of cancer resista...
HER3 (human epidermal growth factor receptor type 3) is a challenging target for diagnostic radionuc...
PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target i...
Human epidermal growth factor receptor type 3 (HER3) plays a crucial role in the progression of many...
Human epidermal growth factor receptor type 3 (HER3) is an emerging therapeutic target in several ma...
Human epidermal growth factor receptor 3 (HER3) is involved in the progression of various cancers an...
PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target i...
Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HE...
Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kina...
Cancer Tissue-Originated Spheroid (CTOS) is a recently developed tissue culture method, in which the...
Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer)...
The human epidermal growth factor receptor 3 (HER3) is an interesting target for antitumor therapy. ...
The humanized monoclonal antibody with high affinity for the human epidermal growth factor receptor ...
PURPOSE: Human epidermal growth factor receptor type 3 (HER3) is a transmembrane receptor tyrosine k...
HER3 (human epidermal growth factor receptor type 3) is a challenging target for diagnostic radionuc...
The human epidermal growth factor receptor 3 (HER3) is involved in the development of cancer resista...
HER3 (human epidermal growth factor receptor type 3) is a challenging target for diagnostic radionuc...
PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target i...
Human epidermal growth factor receptor type 3 (HER3) plays a crucial role in the progression of many...
Human epidermal growth factor receptor type 3 (HER3) is an emerging therapeutic target in several ma...
Human epidermal growth factor receptor 3 (HER3) is involved in the progression of various cancers an...
PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target i...
Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HE...
Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kina...
Cancer Tissue-Originated Spheroid (CTOS) is a recently developed tissue culture method, in which the...
Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer)...